NO20061048L - Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme - Google Patents

Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme

Info

Publication number: NO20061048L
Authority: NO; Norway
Prior art keywords: hydroxymethyl; hydroxy; ester; pharmaceutical compositions; methylpropionic acid
Prior art date: 2003-09-03

Application number

NO20061048A

Other languages

English (en)

Norwegian (no)

Inventor

Muhammad Ashraf

Eric J Benjamin

Ashwinkumar Jain

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2006-03-03

Publication date

2006-05-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061048(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-03 Application filed by Wyeth Corp filed Critical Wyeth Corp

2006-05-24 Publication of NO20061048L publication Critical patent/NO20061048L/no

Links

PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 title abstract 2
150000002148 esters Chemical class 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

NO20061048A 2003-09-03 2006-03-03 Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme NO20061048L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49978903P	2003-09-03	2003-09-03
PCT/US2004/026591 WO2005023254A1 (en)	2003-09-03	2004-08-16	Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same

Publications (1)

Publication Number	Publication Date
NO20061048L true NO20061048L (no)	2006-05-24

Family

ID=34272870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061048A NO20061048L (no)	2003-09-03	2006-03-03	Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme

Country Status (25)

Country	Link
US (2)	US7271177B2 (pt)
EP (1)	EP1660081A1 (pt)
JP (1)	JP2007504226A (pt)
KR (1)	KR20060090803A (pt)
CN (1)	CN1874771A (pt)
AR (1)	AR045559A1 (pt)
AU (1)	AU2004270154A1 (pt)
BR (1)	BRPI0414066A (pt)
CA (1)	CA2536775A1 (pt)
CO (1)	CO5680426A2 (pt)
CR (1)	CR8293A (pt)
EC (1)	ECSP066473A (pt)
GT (1)	GT200400175A (pt)
IL (1)	IL173786A0 (pt)
MX (1)	MXPA06002123A (pt)
NO (1)	NO20061048L (pt)
PA (1)	PA8611201A1 (pt)
PE (1)	PE20050945A1 (pt)
RU (1)	RU2345999C2 (pt)
SA (1)	SA04250334B1 (pt)
SG (1)	SG145716A1 (pt)
TW (1)	TW200510428A (pt)
UA (1)	UA84881C2 (pt)
WO (1)	WO2005023254A1 (pt)
ZA (1)	ZA200601822B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA84881C2 (ru) *	2003-09-03	2008-12-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
EP1701698B1 (en) *	2004-01-08	2008-01-16	Wyeth a Corporation of the State of Delaware	Directly compressible pharmaceutical composition for the oral admimistration of cci-779
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
JP4224115B2 (ja)	2004-04-14	2009-02-12	ワイス	ラパマイシン４２−エステル誘導体の位置特異的合成
CN1946852A (zh) *	2004-04-27	2007-04-11	惠氏公司	利用雷帕霉素特异性甲基化酶标记雷帕霉素
CA2578245C (en)	2004-08-27	2013-10-29	Cardinal Health 529, Llc	Solvent free amorphous rapamycin
MX2007003731A (es) *	2004-09-29	2007-08-14	Johnson & Johnson	Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
CA2595766A1 (en)	2005-02-09	2006-08-17	Wyeth	Cci-779 polymorph and use thereof
CN101321770A (zh) *	2005-12-07	2008-12-10	惠氏公司	由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
AR058282A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
WO2007067566A2 (en) *	2005-12-07	2007-06-14	Wyeth	Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7803818B2 (en) *	2005-12-21	2010-09-28	Eisai R&D Management Co., Ltd.	Amorphous form of 1,2-dihydropyridine compound
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080234657A1 (en) *	2007-03-22	2008-09-25	Medtronic Vascular, Inc.	Methods for contributing to cardiovascular treatments
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) *	2007-07-20	2014-10-07	Medtronic Vascular, Inc.	Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) *	2008-04-24	2009-10-29	Medtronic Vascular, Inc.	Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US20100227799A1 (en) *	2009-03-09	2010-09-09	Medtronic Vascular, Inc.	Simultaneous photodynamic therapy and photo induced polymerization
ES2531040T3 (es) *	2009-05-12	2015-03-10	Corcept Therapeutics Inc	Formas sólidas y procedimiento de preparación
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US8829024B2 (en)	2011-01-07	2014-09-09	Corcept Therapeutics, Inc.	Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en)	2012-05-25	2025-02-18	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
US9951009B2 (en) *	2013-08-29	2018-04-24	Cadila Healthcare Limited	Polymorphic form of pyrrole derivative and intermediate thereof
FI3848027T3 (fi)	2013-11-25	2023-05-04	Corcept Therapeutics Inc	Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
EP3089737B1 (en)	2013-12-31	2021-11-03	Rapamycin Holdings, LLC	Oral rapamycin nanoparticle preparations and use
CA3055076C (en)	2017-03-31	2022-02-22	Corcept Therapeutics, Inc.	Glucocorticoid receptor modulators to treat cervical cancer
US20210154372A1 (en)	2017-05-15	2021-05-27	C.R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
PT115056B (pt) *	2018-10-04	2021-12-10	Hovione Farm Sa	Formas amorfas de agentes quelantes e seus métodos de preparação
EP3880266B1 (en)	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
FI3897589T3 (fi)	2018-12-19	2026-01-13	Corcept Therapeutics Inc	Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
WO2020132046A1 (en)	2018-12-19	2020-06-25	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP7789561B2 (ja)	2019-02-22	2025-12-22	コーセプトセラピューティクス，インコーポレイテッド	レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
EP3952937A1 (en)	2019-04-08	2022-02-16	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
PH12022551430A1 (en)	2019-12-11	2023-11-20	Corcept Therapeutics Inc	Methods of treating antipsychotic-induced weight gain with miricorilant
US11285145B2 (en)	2020-05-27	2022-03-29	Corcept Therapeutics Incorporated	Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
WO2022134033A1 (en)	2020-12-25	2022-06-30	Corcept Therapeutics Incorporated	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL319657A (en)	2022-10-06	2025-05-01	Corcept Therapeutics Inc	Glucocorticoid receptor modulator formulations
WO2024092195A1 (en)	2022-10-28	2024-05-02	Corcept Therapeutics Incorporated	Treatments for amyotrophic lateral sclerosis using dazucorilant
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5985890A (en) *	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
FR2736550B1 (fr) *	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) *	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US5989591A (en)	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
TWI256395B (en) *	1999-09-29	2006-06-11	Wyeth Corp	Regioselective synthesis of rapamycin derivatives
AU2003272489B2 (en)	2002-09-17	2008-11-13	Wyeth	Granulated formulation of the rapamycin ester CCI779
JP4227649B2 (ja) *	2003-08-07	2009-02-18	ワイス	Ｃｃｉ−７７９の位置選択的合成
UA84881C2 (ru) *	2003-09-03	2008-12-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
EP1701698B1 (en) *	2004-01-08	2008-01-16	Wyeth a Corporation of the State of Delaware	Directly compressible pharmaceutical composition for the oral admimistration of cci-779

2004
- 2004-08-16 UA UAA200603517A patent/UA84881C2/ru unknown
- 2004-08-16 KR KR1020067004527A patent/KR20060090803A/ko not_active Abandoned
- 2004-08-16 RU RU2006110568/04A patent/RU2345999C2/ru not_active IP Right Cessation
- 2004-08-16 AU AU2004270154A patent/AU2004270154A1/en not_active Withdrawn
- 2004-08-16 JP JP2006525345A patent/JP2007504226A/ja not_active Withdrawn
- 2004-08-16 CN CNA2004800325370A patent/CN1874771A/zh active Pending
- 2004-08-16 CA CA002536775A patent/CA2536775A1/en not_active Abandoned
- 2004-08-16 WO PCT/US2004/026591 patent/WO2005023254A1/en not_active Ceased
- 2004-08-16 EP EP04781305A patent/EP1660081A1/en not_active Withdrawn
- 2004-08-16 SG SG200805820-8A patent/SG145716A1/en unknown
- 2004-08-16 BR BRPI0414066-4A patent/BRPI0414066A/pt not_active IP Right Cessation
- 2004-08-16 MX MXPA06002123A patent/MXPA06002123A/es active IP Right Grant
- 2004-08-31 US US10/930,487 patent/US7271177B2/en not_active Expired - Fee Related
- 2004-09-01 PE PE2004000844A patent/PE20050945A1/es not_active Application Discontinuation
- 2004-09-01 TW TW093126302A patent/TW200510428A/zh unknown
- 2004-09-02 AR ARP040103142A patent/AR045559A1/es unknown
- 2004-09-03 GT GT200400175A patent/GT200400175A/es unknown
- 2004-09-03 PA PA20048611201A patent/PA8611201A1/es unknown
- 2004-10-12 SA SA4250334A patent/SA04250334B1/ar unknown
2006
- 2006-02-16 IL IL173786A patent/IL173786A0/en unknown
- 2006-03-02 ZA ZA200601822A patent/ZA200601822B/xx unknown
- 2006-03-03 NO NO20061048A patent/NO20061048L/no not_active Application Discontinuation
- 2006-03-16 CR CR8293A patent/CR8293A/es not_active Application Discontinuation
- 2006-03-17 CO CO06027353A patent/CO5680426A2/es unknown
- 2006-04-03 EC EC2006006473A patent/ECSP066473A/es unknown
2007
- 2007-08-10 US US11/891,500 patent/US7446111B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1874771A (zh)	2006-12-06
RU2006110568A (ru)	2007-10-10
AR045559A1 (es)	2005-11-02
AU2004270154A1 (en)	2005-03-17
US7271177B2 (en)	2007-09-18
BRPI0414066A (pt)	2006-10-24
EP1660081A1 (en)	2006-05-31
UA84881C2 (ru)	2008-12-10
CO5680426A2 (es)	2006-09-29
MXPA06002123A (es)	2006-05-17
JP2007504226A (ja)	2007-03-01
WO2005023254A1 (en)	2005-03-17
ECSP066473A (es)	2006-10-10
GT200400175A (es)	2005-04-18
US20050049271A1 (en)	2005-03-03
US20080070950A1 (en)	2008-03-20
ZA200601822B (en)	2008-12-31
CA2536775A1 (en)	2005-03-17
RU2345999C2 (ru)	2009-02-10
PE20050945A1 (es)	2005-12-14
US7446111B2 (en)	2008-11-04
PA8611201A1 (es)	2005-05-10
IL173786A0 (en)	2006-07-05
CR8293A (es)	2006-07-14
TW200510428A (en)	2005-03-16
SA04250334B1 (ar)	2008-05-19
SG145716A1 (en)	2008-09-29
KR20060090803A (ko)	2006-08-16

Legal Events

Date	Code	Title	Description
2010-03-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20061048L (no)	2006-05-24	Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme
BR0314397A (pt)	2005-08-09	Formulações orais
NO20050455L (no)	2005-02-09	Parenterale formuleringer inneholdende en rapamycinhydroksyester
MY137944A (en)	2009-04-30	Specific glucocorticoid compounds having anti-inflammatory activity
MXPA06000407A (es)	2006-03-17	Isomero c cci-779.
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
NO20050828L (no)	2005-04-05	lndol-3-svovelderivater
EA200601554A1 (ru)	2006-12-29	Замещенные индол-о-глюкозиды
NO20044599L (no)	2005-02-16	3-amino-tieno[2,3-b]pyridin-2-karboksysyreamid-forbindelser og fremgangsmater for fremstilling og anvendelser av dem
EA200600317A1 (ru)	2006-06-30	Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
DK1268471T3 (da)	2004-02-09	N-heterocykliske derivater som NOS-inhibitorer
NO20062583L (no)	2006-09-20	Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20062591L (no)	2006-09-20	Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
ES2186550B2 (es)	2003-11-16	Nuevos derivados de oxazolidinonas como antibacterianos.
NO20054787D0 (no)	2005-10-18	Indenderivater som farmasotiske midler
BRPI0518079A (pt)	2008-11-04	usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
ATE359283T1 (de)	2007-05-15	Substituierte pyrazinonverbindungen zur behandlung von entzündungen
BRPI0408423A (pt)	2006-03-21	composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
ATE433450T1 (de)	2009-06-15	Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
EA200300272A1 (ru)	2003-10-30	Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
NO20052994L (no)	2005-07-12	Nye fosforamidderivater.
NO20022000L (no)	2002-06-27	6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
FR2894579B1 (fr)	2008-01-18	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
NO20061343L (no)	2006-03-24	Imidazo[4,5-b]pyridinderivater som induserbare NO-syntaseinhibitorer
WO2004093796A3 (en)	2005-09-09	Lactam derivatives and methods of their use